Literature DB >> 3012622

Epstein Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis.

L K Borysiewicz, S J Haworth, J Cohen, J Mundin, A Rickinson, J G Sissons.   

Abstract

In a number of patients recovery from infectious mononucleosis (IM) following primary Epstein Barr virus (EBV) infection, is complicated by the persistence of symptoms for months or years. Normally recovery from infectious mononucleosis is associated with the development of EBV-specific antibodies and memory cytotoxic T-cells, which are present in the peripheral blood of all normal seropositive individuals. We studied four patients who had persistent symptoms for more than two years after infectious mononucleosis to determine if this abnormality was associated with a defect in EBV-specific or non-specific immune responses. All four patients had normal immunoglobulin concentrations, T- and B-cell numbers, T-cell proliferative responses and natural killer cell activity. However three of the four had reduced or absent antibodies to the EBV nuclear antigen (EBNA) although other EBV-specific antibody titres were normal. All four also had reduced EBV-specific cytotoxic T-cell activity as measured by the EBV regression assay. This defect was probably EBV-specific as alloreactive cytotoxic T-cell responses were normal. In addition, three of three patients tested had reduced in vitro antibody synthesis following pokeweed mitogen stimulation. These studies indicate that the syndrome of persistent symptoms following EBV mononucleosis may be associated with a defect in EBV-specific immunity, and thus suggest a possible immunological basis for the syndrome.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3012622

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  10 in total

Review 1.  Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review.

Authors:  Bridget Candy; Trudie Chalder; Anthony J Cleare; Simon Wessely; Peter D White; Matthew Hotopf
Journal:  Br J Gen Pract       Date:  2002-10       Impact factor: 5.386

2.  Biological responses to overload training in endurance sports.

Authors:  R W Fry; A R Morton; P Garcia-Webb; G P Crawford; D Keast
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1992

3.  Immunologic abnormalities in chronic fatigue syndrome.

Authors:  N G Klimas; F R Salvato; R Morgan; M A Fletcher
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

4.  Seroepidemiological study of infectious mononucleosis in older patients.

Authors:  S M Kirov; K A Marsden; S Wongwanich
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

Review 5.  [Chronic fatigue syndrome].

Authors:  S Ewig; H J Dengler
Journal:  Klin Wochenschr       Date:  1990-08-17

6.  Antibody to Coxsackie B virus in diagnosing postviral fatigue syndrome.

Authors:  N A Miller; H A Carmichael; B D Calder; P O Behan; E J Bell; R A McCartney; F C Hall
Journal:  BMJ       Date:  1991-01-19

7.  Characterization of cytokine production in infectious mononucleosis studied at a single-cell level in tonsil and peripheral blood.

Authors:  J Andersson; U Andersson
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

8.  High levels of type 2 cytokine-producing cells in chronic fatigue syndrome.

Authors:  A Skowera; A Cleare; D Blair; L Bevis; S C Wessely; M Peakman
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

9.  Psychological and immunological correlates of acute overtraining.

Authors:  R W Fry; J R Grove; A R Morton; P M Zeroni; S Gaudieri; D Keast
Journal:  Br J Sports Med       Date:  1994-12       Impact factor: 13.800

Review 10.  Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics.

Authors:  Gerwyn Morris; Michael Maes
Journal:  BMC Med       Date:  2013-09-17       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.